Digestive Diseases and Sciences

, Volume 60, Issue 2, pp 436–443 | Cite as

Aspirin and Nonsteroidal Anti-Inflammatory Drug Use and the Risk of Barrett’s Esophagus

  • Jennifer L. Schneider
  • Wei K. Zhao
  • Douglas A. Corley
Original Article

Abstract

Background

The use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) may decrease the risk of esophageal adenocarcinoma; however, it is unknown where these agents may act in the proposed pathway from normal mucosa to Barrett’s esophagus to esophageal adenocarcinoma.

Aim

The aim of the study was to evaluate the association between aspirin and NSAID use and Barrett’s esophagus in a case–control study within a large community-based population.

Methods

We conducted a case–control study of aspirin/NSAID use and Barrett’s esophagus within the Kaiser Permanente Northern California population. Cases had a new diagnosis of Barrett’s esophagus between October 2002 and September 2005; controls were members without a diagnosis of Barrett’s esophagus.

Results

Persons with Barrett’s esophagus were less likely to use aspirin than population controls [odds ratio (OR) 0.59, 95 % confidence interval (CI) 0.39–0.87]; a stronger association was found among cases and controls with reflux symptoms (OR 0.49, 95 % CI 0.32–0.75; p value interaction = 0.004). Similar associations were found with the use of either aspirin and/or non-aspirin NSAIDs (OR 0.53, 95 % CI 0.35–0.81), although NSAID use alone was not significantly associated with Barrett’s esophagus (OR 0.74, 95 % CI 0.47–1.16). The strength of the association was highest among persons with at least moderate-to-high total medication intake.

Conclusions

Regular use of aspirin or NSAIDs was associated with a decreased risk of Barrett’s esophagus, particularly among persons with gastroesophageal reflux disease symptoms. These findings have implications for chemoprevention, as some of the previously described protective association between aspirin/NSAIDs and esophageal adenocarcinoma may be explained by events that occur prior to the development of Barrett’s esophagus.

Keywords

Chemoprevention Esophageal cancer NSAID Barrett’s esophagus 

References

  1. 1.
    Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62:118–128.Google Scholar
  2. 2.
    Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330.PubMedCrossRefGoogle Scholar
  3. 3.
    Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology. 2000;119:333–338.PubMedCrossRefGoogle Scholar
  4. 4.
    Spechler SJ, Jain SK, Tendler DA, Parker RA. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16:1795–1800.PubMedCrossRefGoogle Scholar
  5. 5.
    Reid BJ, Barrett MT, Galipeau PC, et al. Barrett’s esophagus: ordering the events that lead to cancer. Eur J Cancer Prev. 1996;5:57–65.PubMedCrossRefGoogle Scholar
  6. 6.
    Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett’s metaplasia has regional variations in the west. Gastroenterology. 2002;122:588–590.PubMedCrossRefGoogle Scholar
  7. 7.
    Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol. 2005;6:945–952.PubMedCrossRefGoogle Scholar
  8. 8.
    Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003;124:47–56.PubMedCrossRefGoogle Scholar
  9. 9.
    Aspirin reduces esophageal-cancer risk in people with most-aggressive form of Barrett’s esophagus; 2007. http://www.sciencedaily.com/releases/2007/02/070227105902.htm. Accessed 21 Sept 2011.
  10. 10.
    Anderson LA, Johnston BT, Watson RG, et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res. 2006;66:4975–4982.PubMedCrossRefGoogle Scholar
  11. 11.
    Jayaprakash V, Menezes RJ, Javle MM, et al. Regular aspirin use and esophageal cancer risk. Int J Cancer. 2006;119:202–207.PubMedCrossRefGoogle Scholar
  12. 12.
    Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012;142:442–452.Google Scholar
  13. 13.
    Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology. 2010;138:2260–2266.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Wang F, Lv ZS, Fu YK. Nonsteroidal anti-inflammatory drugs and esophageal inflammation—Barrett’s esophagus—adenocarcinoma sequence: a meta-analysis. Dis Esophagus. 2010;1:1–10.Google Scholar
  15. 15.
    Oyama K, Fujimura T, Ninomiya I, et al. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis. 2005;26:565–570.PubMedCrossRefGoogle Scholar
  16. 16.
    Omer ZB, Ananthakrishnan AN, Nattinger KJ, et al. Aspirin protects against Barrett’s esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2012;10:722–727.Google Scholar
  17. 17.
    Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82:703–710.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus Gastroenterology. 2007;133:34–41; quiz 311.Google Scholar
  19. 19.
    Rothman KJGS. Modern Epidemiology. Phildadeplphia, PA: Lippincott-Raven; 1998.Google Scholar
  20. 20.
    Locke GR, Talley NJ, Weaver AL, Zinsmeister AR. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc. 1994;69:539–547.PubMedCrossRefGoogle Scholar
  21. 21.
    Zhao Y, Ash AS, Ellis RP, et al. Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Med Care. 2005;43:34–43.PubMedGoogle Scholar
  22. 22.
    Zhao Y, Ellis RP, Ash AS, et al. Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. Health Serv Res. 2001;36:180–193.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Thrift AP, Pandeya N, Smith KJ, et al. Helicobacter pylori infection and the risks of Barrett’s oesophagus: a population-based case-control study. Int J Cancer. 2012;130:2407–2416.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Kuo CJ, Lin CH, Liu NJ, et al. Frequency and risk factors for Barrett’s esophagus in Taiwanese patients: a prospective study in a tertiary referral center. Dig Dis Sci. 2010;55:1337–1343.PubMedCrossRefGoogle Scholar
  25. 25.
    Pilotto A, Franceschi M, Leandro G, et al. Clinical features of reflux esophagitis in older people: a study of 840 consecutive patients. J Am Geriatr Soc. 2006;54:1537–1542.PubMedCrossRefGoogle Scholar
  26. 26.
    Park JJ, Kim JW, Kim HJ, et al. The prevalence of and risk factors for Barrett’s esophagus in a Korean population: a nationwide multicenter prospective study. J Clin Gastroenterol. 2009;43:907–914.PubMedCrossRefGoogle Scholar
  27. 27.
    Ruder EH, Laiyemo AO, Graubard BI, et al. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011;106:1340–1350.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Pasricha PJ, Bedi A, O’Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology. 1995;109:994–998.PubMedCrossRefGoogle Scholar
  29. 29.
    Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993;80:1618–1619.PubMedCrossRefGoogle Scholar
  30. 30.
    Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991;101:635–639.PubMedGoogle Scholar
  31. 31.
    Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252–266.PubMedCrossRefGoogle Scholar
  32. 32.
    Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus. Gastroenterology. 2002;122:1101–1112.PubMedCrossRefGoogle Scholar
  33. 33.
    Esquivias P, Morandeira A, Escartin A, et al. Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats. World J Gastroenterol. 2012;18:4866–4874.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Tsibouris P, Vlachou E, Isaacs P. Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett’s esophagus. World J Gastrointest Pharmacol Ther. 2014;5:27–39.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Nalamachu S, Pergolizzi J, Raffa R, Lakkireddy D, Taylor RJ. Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity. Expert Opin Drug Saf. 2014;13:903–917.PubMedCrossRefGoogle Scholar
  36. 36.
    Bavry A, Thomas F, Allison M, et al. Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women’s health initiative. Circ Cardiovasc Qual Outcomes. 2014;7:603–610.PubMedCrossRefGoogle Scholar
  37. 37.
    Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:97–102.PubMedGoogle Scholar
  38. 38.
    Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: behavioral risk factor surveillance system. Am J Prev Med. 2006;30:74–77.PubMedCrossRefGoogle Scholar
  39. 39.
    2005 Kaiser Permanente Adult Member Health Survey Report for the Northern California Region Membership; 2007. http://www.dor.kaiser.org/external/DORExternal/mhs/2005_ncal_report.aspx. Accessed 7 Mar 2013.
  40. 40.
    Cook MB, Wild CP, Everett SM, et al. Risk of mortality and cancer incidence in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2007;16:2090–2096.PubMedCrossRefGoogle Scholar
  41. 41.
    Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161–169.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Jennifer L. Schneider
    • 1
  • Wei K. Zhao
    • 1
  • Douglas A. Corley
    • 1
  1. 1.Kaiser Permanente Division of ResearchOaklandUSA

Personalised recommendations